Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 4/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352140 | 0.92 | RAD52 (0.56) | CCNA2CDK2CCNA1PTGS2PTGS1 | |
| SCHEMBL11868715 | 0.87 | RAD52 (0.68) | CCNA2CDK2CCNA1RAD52KDM4E | |
| SCHEMBL5258632 | 0.87 | PTGS2 (0.52) | CCNA2CDK2CCNA1PTGS2PTGS1 | |
| SCHEMBL6353347 | 0.83 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL6344383 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1RAD52CA1CA2 | |
| SCHEMBL6352141 | 0.83 | PTGS2 (0.51) | CCNA2CDK2CCNA1PTGS2PTGS1 | |
| SCHEMBL11865536 | 0.82 | RAD52 (0.61) | CCNA2CDK2CCNA1RAD52IKBKB | |
| Hydrochloric Acid SCHEMBL6800512 | 0.81 | PTGS2 (0.51) | CCNA2CDK2CCNA1PTGS2PTGS1 | |
| SCHEMBL6789944 | 0.81 | CCNA2 (0.52) | CCNA2CDK2CCNA1PTGS2PTGS1 | |
| SCHEMBL11867763 | 0.80 | RAD52 (0.70) | CCNA2CDK2CCNA1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0923933-B1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | SEARLE & CO (US) | 2002-07-03 | — | — | EP | claimed |
| EP-0924201-B1 | Tricyclic-substituted pyrazolyl benzenesulfonamides and their use as cyclooxygenase II inhibitors | SEARLE & CO (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
| US-6951949-B2 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | CCNA2 3290/4885CDK2 2068/4885CCNA1 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.